Stock Analiz

Ocugen, Inc. OCGN

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2014 · data as of November 13, 2026

$0.83Market cap $281M
Open the interactive analysis →

Ocugen, Inc. (OCGN) is a healthcare company listed in the US with a market value of about $281M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$65M, a net margin of -1367.6%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 152% a year, a 5-year average ROIC of -132%.

About Ocugen

Ocugen is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2014. Revenue went from $43000 in 2020 to $4M in 2025, growth of about 152.5% a year. It was profitable in 0 of the last 6 years in our data. Its share count rose by 58% over three years (dilution for shareholders). It spends 901% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth2/5
Track record2/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • ROE above 15%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S58.8
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-22.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)8.8%
Revenue growth (5 yrs, per year)152.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1851.1%
ROIC (5-yr avg.)-131.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$5M$4M$4M$6M$2M$0$43000
Net income-$65M-$68M-$54M-$63M-$87M-$58M-$22M
Free cash flow-$64M-$57M-$46M-$73M-$65M-$49M-$15M
EPS (diluted)$-0.20$-0.20—$-0.26$-0.40$-0.30$-0.31
Net margin-1367.6%-1537.4%-1333.0%-1045.0%-3488.9%—-50748.8%
ROIC—-265.6%-83.0%-137.9%-110.9%-61.4%-88.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 6 analysts is $12.17, 1370% above the current price; targets range from $8.00 to $22.00; the consensus rating is “Strong buy”; expected EPS is $-0.20 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Ocugen pay a dividend?

Not currently.

Is Ocugen a good stock to buy?

We do not give buy or sell advice. Ocugen scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.